Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204)

Name: Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204)
Published: 2016
License: Public Domain

Merck Sharp & Dohme LLC · 2016

ClinicalTrials.gov · Datasets · License: Public Domain · 2016

Open Source ↗

hodgkin lymphoma, programmed cell death-1 (pd1, pd-1), programmed death-ligand 1 (pdl1, pd-l1), interventional, phase3

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204)

Related documents